A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Inclusion criteria

• ✓. Greater than or equal to (\>=) 2 active joints at screening and baseline, with at least 14 consecutive days of temperature recordings, which may include the presence or absence of fever (\>=38 degree Celsius) during the time between screening and baseline; or
• ✓. \>=2 active joints at screening and baseline, with a fever \>=38 degree Celsius for at least 5 consecutive days during the time between screening and baseline; under these circumstances a participant does not need to complete a full 14 days of temperature diary entries to meet this inclusion criteria
• ✓. Etanercept must have been discontinued within \>= 2 weeks prior to baseline
• ✓. Anakinra must have been discontinued within \>= 4 days prior to baseline
• ✓. Abatacept must have been discontinued within \>= 12 weeks prior to baseline
• ✓. Infliximab or adalimumab must have been discontinued within \>= 8 weeks prior to baseline
• ✓. Canakinumab must have been discontinued within \>= 20 weeks prior to baseline
• ✓. Rilonacept must have been discontinued within \>= 6 weeks prior to baseline